This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

This study has been completed.
Information provided by:
Asociación para Evitar la Ceguera en México Identifier:
First received: December 1, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted
Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Condition Intervention Phase
Vogt Koyanagi Harada Disease Serpiginous Choroiditis Multifocal Choroiditis Drug: Bevacizumab Procedure: Intravitreal Injection of Bevacizumab Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Resource links provided by NLM:

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • Best corrected visual acuity
  • Retinal thickness by OCT
  • Leakage in Fluorescein angiogram

Study Start Date: August 2006
Estimated Study Completion Date: November 2006

Ages Eligible for Study:   25 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical Diagnose
  • Patient Consent
  • Chronic stage of inflammation

Exclusion Criteria:

  • only eye
  • age lower than 30 yo.
  • Systemic condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00407121

Asociacion para Evitar la Ceguera en Mexico
Mexico, Distrito Federal, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Principal Investigator: Veronica Kon-Jara, MD Asociación para Evitar la Ceguera en México
Study Chair: LuzElena Concha-Del Rio, MD Asociación para Evitar la Ceguera en México
  More Information Identifier: NCT00407121     History of Changes
Other Study ID Numbers: APEC-0025
Study First Received: December 1, 2006
Last Updated: December 1, 2006

Keywords provided by Asociación para Evitar la Ceguera en México:
Neovascular Membrane

Additional relevant MeSH terms:
Uveomeningoencephalitic Syndrome
Choroid Diseases
Uveal Diseases
Eye Diseases
Uveitis, Posterior
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Autoimmune Diseases
Immune System Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on August 23, 2017